Neoadjuvant osimertinib shows promise for EGFR-mutated NSCLC

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Mar 31 / Springer Healthcare

Neoadjuvant osimertinib shows promise for EGFR-mutated NSCLC

Oncology Lung Cancer ELCC-2022

Description

Chao Lyu discusses the final efficacy and safety results from the NEOS trial, demonstrating the benefits of osimertinib for EGFR-mutated resectable stage II-IIIB lung adenocarcinoma in the neoadjuvant setting.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.